BioCentury
ARTICLE | Clinical News

Bayer's Amikacin Inhale misses in Phase III for Gram-negative pneumonia

December 8, 2017 7:02 PM UTC

Bayer AG (Xetra:BAYN) reported data from the double-blind, international Phase III INHALE program in 725 intubated and mechanically-ventilated patients with Gram-negative pneumonia showing that Amikacin Inhale (BAY41-6551, NKTR-061) plus standard of care (SOC) missed the primary endpoint of improving survival at day 28-32 vs. placebo plus SOC. Amikacin Inhale plus SOC also missed the secondary endpoints of improving pneumonia-related mortality through to day 28-32, early clinical response up to day 10, number of days on mechanical ventilation up to day 28-32 and number of intensive care unit (ICU) days up to day 28-32 vs. placebo plus SOC.

Patients received SOC IV antibiotics plus placebo or 400 mg Amikacin Inhale every 12 hours for 10 days...

BCIQ Company Profiles

Bayer AG

Nektar Therapeutics

BCIQ Target Profiles

Ribosomal 30S subunit